NVCR NovoCure Limited Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

NVCR [NASD]

NovoCure Limited

Healthcare | Medical Instruments & Supplies | USA

statements

Index	-	P/E	-	EPS (ttm)	-0.03	Insider Own	1.40%	Shs Outstand	99.88M	Perf Week	-0.45%
Market Cap	6.03B	Forward P/E	135.99	EPS next Y	0.44	Insider Trans	-23.88%	Shs Float	83.80M	Perf Month	-11.06%
Income	-2.40M	PEG	-	EPS next Q	0.00	Inst Own	71.10%	Short Float	4.03%	Perf Quarter	-13.74%
Sales	379.80M	P/S	15.89	EPS this Y	89.30%	Inst Trans	-0.38%	Short Ratio	3.40	Perf Half Y	-25.47%
Book/sh	2.42	P/B	24.95	EPS next Y	307.34%	ROA	1.90%	Target Price	79.57	Perf Year	-12.67%
Cash/sh	3.31	P/C	18.22	EPS next 5Y	-	ROE	4.40%	52W Range	53.40 - 98.84	Perf YTD	-28.35%
Dividend	-	P/FCF	298.67	EPS past 5Y	40.20%	ROI	0.20%	52W High	-38.51%	Beta	1.52
Dividend %	-	Quick Ratio	5.20	Sales past 5Y	86.70%	Gross Margin	75.40%	52W Low	13.81%	ATR	2.56
Employees	782	Current Ratio	5.50	Sales Q/Q	38.90%	Oper. Margin	0.50%	RSI (14)	48.63	Volatility	3.55% 4.29%
Optionable	Yes	Debt/Eq	0.62	EPS Q/Q	42.80%	Profit Margin	2.30%	Rel Volume	0.30	Prev Close	60.38
Shortable	Yes	LT Debt/Eq	0.62	Earnings	Jul 30 BMO	Payout	0.00%	Avg Volume	994.21K	Price	60.78
Recom	2.60	SMA20	-0.82%	SMA50	-4.07%	SMA200	-18.61%	Volume	70,294	Change	0.65%

Jun-01-20

Resumed

Oppenheimer

Perform

May-01-20

Downgrade

Oppenheimer

Outperform → Perform

Apr-09-20

Downgrade

Evercore ISI

In-line → Underperform

$58

Mar-05-20

Upgrade

Wells Fargo

Equal Weight → Overweight

$85 → $90

Jan-02-20

Downgrade

Evercore ISI

Outperform → In-line

$84 → $90

Jul-29-19

Upgrade

SunTrust

Hold → Buy

Jul-26-19

Downgrade

Wedbush

Outperform → Neutral

$57 → $80

Jul-26-19

Downgrade

JP Morgan

Overweight → Neutral

$61 → $79

Mar-20-19

Initiated

SunTrust

Hold

Nov-02-18

Downgrade

Wells Fargo

Outperform → Market Perform

Jul-16-18

Initiated

Evercore ISI

Outperform

$46

Apr-18-18

Reiterated

Mizuho

Buy

$28 → $32

Feb-23-18

Reiterated

Mizuho

Buy

$25 → $28

May-24-17

Upgrade

Wells Fargo

Market Perform → Outperform

Jul-29-16

Reiterated

Wedbush

Outperform

$30 → $20

Jan-19-16

Initiated

Barclays

Underweight

$16

Dec-02-15

Initiated

Deutsche Bank

Hold

$28

Oct-27-15

Initiated

Wedbush

Outperform

Oct-27-15

Initiated

JP Morgan

Overweight

Oct-27-15

Initiated

JMP Securities

Mkt Outperform

$43

Jul-12-20 08:54PM	Did Hedge Funds Make The Right Call On NovoCure Limited (NVCR) ? Insider Monkey
Jul-08-20 07:30AM	Novocure Announces Over 100 Physicians in the U.S. Now Certified to Prescribe Optune Lua Business Wire
06:00AM	The 2 Little-Known Growth Stocks I Bought Last Week Motley Fool
Jul-07-20 07:30AM	Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer Business Wire -5.22%
Jul-01-20 07:30AM	Novocure to Report Second Quarter 2020 Financial Results Business Wire
Jun-18-20 12:02PM	Has NovoCure Limited (NASDAQ:NVCR) Stock's Recent Performance Got Anything to Do With Its Financial Health? Simply Wall St.
Jun-08-20 01:07AM	Hedge Funds Have Never Been This Bullish On NovoCure Limited (NVCR) Insider Monkey
Jun-02-20 07:30AM	Novocure Announces Launch of MyLink to Enable Patient-Guided, Remote Download of Optune® Usage Data Business Wire
May-13-20 10:10AM	China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma Business Wire
May-05-20 11:30PM	Edited Transcript of NVCR earnings conference call or presentation 30-Apr-20 12:00pm GMT Thomson Reuters StreetEvents
May-04-20 10:21AM	Is NovoCure Limited (NASDAQ:NVCR) Potentially Undervalued? Simply Wall St.
May-02-20 11:30AM	NovoCure Limited (NVCR) Q1 2020 Earnings Call Transcript Motley Fool
Apr-30-20 04:05PM	Highly Rated Cancer Play Tumbles As Key Studies Delayed Amid Outbreak Investor's Business Daily -10.52%
07:30AM	NovoCure (NVCR) Lags Q1 Earnings and Revenue Estimates Zacks
06:00AM	Novocure Reports First Quarter 2020 Financial Results and Provides Company Update Business Wire
Apr-27-20 07:30AM	Novocure Announces Presentation of EF-19 Post-approval Registry Trial Data Studying Optune as a Monotherapy for the Treatment of Recurrent GBM at the American Association for Cancer Research 2020 Virtual Annual Meeting I Business Wire
Apr-23-20 12:32PM	NovoCure (NVCR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
Apr-07-20 03:07PM	Is NovoCure (NASDAQ:NVCR) A Risky Investment? Simply Wall St. -6.60%
09:00AM	Medical Services Outlook Bright Amid Coronavirus Crisis Zacks
Apr-03-20 07:30AM	Novocure Provides Business Update Related to COVID-19 Business Wire
Mar-23-20 12:24AM	Hedge Funds Started Selling NovoCure Limited (NVCR) Before The Coronavirus Insider Monkey
Mar-20-20 09:16AM	German Federal Joint Committee Updates Medical Care Directive to include Tumor Treating Fields, establishing National Reimbursement for Optune in Germany Business Wire -6.68%
Mar-19-20 07:30AM	Novocure Announces Optune Lua as the Brand Name for the NovoTTF-100L System Business Wire +9.50%
Mar-12-20 07:30AM	Preclinical Data Show Tumor Treating Fields Induces Immunogenic Cell Death Resulting in Enhanced Antitumor Efficacy When Combined with Anti-PD-1 Therapy Business Wire
Mar-10-20 03:18AM	Edited Transcript of NVCR earnings conference call or presentation 27-Feb-20 1:00pm GMT Thomson Reuters StreetEvents
Feb-27-20 07:30AM	NovoCure (NVCR) Q4 Earnings and Revenues Beat Estimates Zacks
06:00AM	Novocure Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Company Update Business Wire
Feb-20-20 12:31PM	NovoCure (NVCR) Earnings Expected to Grow: Should You Buy? Zacks
Feb-11-20 08:54AM	Is NovoCure Limited's (NASDAQ:NVCR) CEO Paid Enough Relative To Peers? Simply Wall St.
Feb-05-20 09:15AM	NASDAQ Reaches New Closing High as Rebound Continues Zacks
Feb-04-20 02:56PM	Expand Your Portfolio with this First Profit Stock Screener Zacks
Jan-29-20 09:15AM	Relief Rally Snaps the Dow's 5-Day Losing Skid Zacks
Jan-23-20 07:24AM	The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment Benzinga
Jan-21-20 04:35PM	Why This Leading Medtech Stock Nabbed A Second Breakout In A Week Investor's Business Daily
07:40AM	Novocure Announces National Reimbursement in Israel for Optune® in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma Business Wire
Jan-17-20 10:17AM	Stock Market Sets More Record Highs; Home Depot, Pinterest, Tesla, Twitter Key Movers Investor's Business Daily
Jan-16-20 04:45PM	IBD Stock Of The Day Breaks Out On Bullish Preliminary Sales Report Investor's Business Daily +11.84%
Jan-13-20 06:00AM	Novocure Announces Fourth Quarter and Full Year 2019 Preliminary Net Revenues and Provides Company Update Business Wire
Jan-09-20 07:30AM	Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer GlobeNewswire
Jan-03-20 08:40AM	Small-cap woes highlight stock markets dependency on mega-cap names MarketWatch
Dec-26-19 07:30AM	Novocure to Participate in the 38th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-08-19 07:11PM	Heres What Hedge Funds Think About NovoCure Limited (NVCR) Insider Monkey
Dec-04-19 04:05PM	SI-BONE Names Jeryl (Jeri) Hilleman to Board of Directors GlobeNewswire
09:55AM	Raise Stops on NovoCure TheStreet.com
Dec-02-19 07:30AM	Novocure and the AACR Announce 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program Business Wire
05:00AM	Novocure- A New Way to Target Tumors MoneyShow
Nov-26-19 07:30AM	Novocure to Participate in the Evercore ISI 2019 HealthCONx Conference TEST Business Wire Releases
07:30AM	Novocure to Participate in the Evercore ISI 2019 HealthCONx Conference Business Wire
Nov-20-19 07:30AM	Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology Business Wire
Nov-04-19 09:35AM	Edited Transcript of NVCR earnings conference call or presentation 31-Oct-19 12:00pm GMT Thomson Reuters StreetEvents
Nov-01-19 11:10AM	NovoCure Looks Ready to Resume Its Strong Uptrend After a Correction TheStreet.com +5.19%
Oct-31-19 07:35AM	NovoCure (NVCR) Q3 Earnings and Revenues Beat Estimates Zacks
06:00AM	Novocure Reports Third Quarter 2019 Financial Results and Provides Company Update Business Wire
06:00AM	Novocure Ltd. to Host Earnings Call ACCESSWIRE
Oct-27-19 10:08AM	3 Monster Growth Stocks to Hold Through 2020 TipRanks
Oct-24-19 10:32AM	Will NovoCure (NVCR) Report Negative Earnings Next Week? What You Should Know Zacks
Oct-18-19 07:35AM	Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar? Zacks
Oct-16-19 10:31AM	Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy in Malignant Pleural Mesothelioma Published in The Lancet Oncology Business Wire
Oct-14-19 06:13PM	Did Hedge Funds Drop The Ball On NovoCure Limited (NVCR) ? Insider Monkey
01:31PM	How Many NovoCure Limited (NASDAQ:NVCR) Shares Have Insiders Sold, In The Last Year? Simply Wall St.
Oct-01-19 07:30AM	Novocure to Report Third Quarter 2019 Financial Results Business Wire
Sep-13-19 06:59PM	Novocure (NVCR) CFO Wilhelmus Cm Groenhuysen Sold $3.9 million of Shares GuruFocus.com
Sep-11-19 07:15PM	Novocure (NVCR) CFO Wilhelmus Cm Groenhuysen Sold $3.9 million of Shares GuruFocus.com
Sep-09-19 11:34AM	10 Stocks to Sell in Market-Cursed September InvestorPlace -8.23%
09:25AM	Novocure Announces 27 Presentations at the American Society for Radiation Oncology 2019 Annual Meeting Business Wire
Sep-04-19 09:44AM	Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar? Zacks
Aug-30-19 06:54PM	Small-Cap Stocks Show Stealth Buying Pattern Investopedia
Aug-29-19 08:50AM	Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load? Simply Wall St.
Aug-27-19 11:37AM	Jim Cramer Gives His Opinion On Novocure, Morgan Stanley And More Benzinga
Aug-14-19 05:38AM	Novocure's Charts Are as Bullish As They Get, So Here's My Strategy TheStreet.com
Aug-13-19 07:01AM	Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar? Zacks
Aug-12-19 07:30AM	China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China GlobeNewswire
07:30AM	China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China Business Wire
Aug-07-19 11:17AM	Jim Cramer Weighs In On Funko, Citigroup And More Benzinga
10:26AM	NovoCure Looks Due for a Technical Correction TheStreet.com
Aug-06-19 09:01AM	Novocure to Participate in Three Upcoming Investor Conferences Business Wire
Aug-04-19 07:00PM	Why NovoCure Stock Soared 32% in July Motley Fool
Jul-31-19 01:13AM	NovoCure Limited (NVCR) Q2 2019 Earnings Call Transcript Motley Fool
Jul-30-19 12:32AM	Edited Transcript of NVCR earnings conference call or presentation 25-Jul-19 12:00pm GMT Thomson Reuters StreetEvents
Jul-26-19 08:57AM	NovoCure Limited (NVCR) Shares March Higher, Can It Continue? Zacks
Jul-25-19 02:52PM	Why NovoCure Stock Is Surging Today Motley Fool +8.58%
01:59PM	NovoCure Nears Profitability as Revenue Continues to Soar Motley Fool
07:30AM	NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates Zacks
06:00AM	Novocure Reports Second Quarter 2019 Financial Results and Provides Company Update Business Wire
Jul-24-19 07:54AM	Are Investors Undervaluing NovoCure Limited (NASDAQ:NVCR) By 43%? Simply Wall St.
Jul-22-19 10:11AM	Can NovoCure's (NVCR) Steady Optune Business Aid Q2 Earnings? Zacks
07:30AM	Novocure Announces 10 Oral Presentations and a Special Session on Tumor Treating Fields at the 41st International Engineering in Medicine and Biology Conference Business Wire
Jul-18-19 07:11PM	CMS Establishes 2019 Monthly Fee Schedule Amount for Optune® Business Wire
10:33AM	NovoCure (NVCR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Zacks
06:57AM	Medicare Releases Final Local Coverage Determination Providing Coverage of Optune® for Newly Diagnosed Glioblastoma Business Wire
Jul-05-19 03:32PM	Novocure Stock Gave Quick Swing Trading Profit Investor's Business Daily
Jul-03-19 08:21AM	Why NovoCure Stock Jumped 19% in June Motley Fool
Jul-02-19 07:15PM	Novocure Ltd (NVCR) CEO Asaf Danziger Sold $11.7 million of Shares GuruFocus.com
07:30AM	Novocure to Report Second Quarter 2019 Financial Results Business Wire
Jun-29-19 06:00AM	3 Cancer-Treatment Stocks to Buy Motley Fool
Jun-28-19 09:00AM	NovoCure (NVCR) Jumps: Stock Rises 7.1% Zacks
Jun-26-19 07:30AM	German Institute for Quality and Efficiency in Healthcare Publishes Rapid Report Noting Optunes Survival Benefit for Patients with Newly Diagnosed Glioblastoma Business Wire
Jun-24-19 08:22AM	What does NovoCure Limited's (NASDAQ:NVCR) Balance Sheet Tell Us About Its Future? Simply Wall St.
Jun-19-19 07:15PM	Novocure Ltd (NVCR) CEO Asaf Danziger Sold $11.3 million of Shares GuruFocus.com
Jun-18-19 10:44AM	Novocure Could Climb Even Further; Here's Where to Buy TheStreet.com

Markets a wearable electric field device for treating glioblastoma brain cancer.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Benaim Ely	Chief Medical Officer	May 12	Sale	64.78	2,595	168,104	12,616	May 14 04:14 PM
DOYLE WILLIAM F	Executive Chairman	May 11	Sale	63.73	31,332	1,996,726	649,958	May 12 04:13 PM
Benaim Ely	Chief Medical Officer	May 11	Sale	63.73	1,611	102,666	15,211	May 12 04:22 PM
DOYLE WILLIAM F	Executive Chairman	May 08	Option Exercise	63.84	58,767	3,751,685	713,193	May 11 04:17 PM
Benaim Ely	Chief Medical Officer	May 08	Option Exercise	63.84	4,206	268,511	16,822	May 12 04:22 PM
Weinberg Uri	Chief Science Officer	May 08	Option Exercise	63.84	1,402	89,504	25,629	May 11 04:22 PM
DOYLE WILLIAM F	Executive Chairman	May 08	Sale	63.50	31,903	2,025,872	681,290	May 11 04:17 PM
DOYLE WILLIAM F	Executive Chairman	May 07	Option Exercise	64.77	58,768	3,806,403	685,419	May 11 04:17 PM
DOYLE WILLIAM F	Executive Chairman	May 07	Sale	64.74	30,993	2,006,518	654,426	May 11 04:17 PM
DOYLE WILLIAM F	Executive Chairman	May 06	Option Exercise	64.15	58,768	3,769,967	626,651	May 07 04:41 PM
DOYLE WILLIAM F	Executive Chairman	May 06	Sale	64.27	29,881	1,920,452	567,883	May 07 04:41 PM
DOYLE WILLIAM F	Executive Chairman	May 05	Option Exercise	61.40	58,768	3,608,355	628,047	May 07 04:41 PM
Shah Pritesh	Chief Commercial Officer	May 05	Sale	62.20	1,149	71,468	100,693	May 07 04:48 PM
DOYLE WILLIAM F	Executive Chairman	May 05	Sale	62.47	30,283	1,891,718	597,764	May 07 04:41 PM
DOYLE WILLIAM F	Executive Chairman	May 04	Option Exercise	60.48	58,768	3,554,289	569,279	May 06 05:52 PM
Shah Pritesh	Chief Commercial Officer	May 04	Sale	60.08	1,184	71,134	101,842	May 05 04:32 PM
Shah Pritesh	Chief Commercial Officer	May 01	Option Exercise	65.80	2,333	153,511	103,026	May 05 04:32 PM
Ambrogi Michael J.	Chief Operating Officer	Apr 14	Option Exercise	7.15	35,745	255,577	256,612	Apr 15 05:03 PM
Ambrogi Michael J.	Chief Operating Officer	Apr 14	Sale	71.00	27,519	1,953,970	220,867	Apr 15 05:03 PM
Ambrogi Michael J.	Chief Operating Officer	Apr 13	Option Exercise	7.15	22,755	162,698	243,622	Apr 15 05:03 PM
Ambrogi Michael J.	Chief Operating Officer	Apr 13	Sale	69.32	30,981	2,147,594	220,867	Apr 15 05:03 PM
Shah Pritesh	Chief Commercial Officer	Mar 06	Option Exercise	7.48	17,500	130,900	103,938	Mar 10 04:20 PM
DOYLE WILLIAM F	Executive Chairman	Mar 06	Sale	69.53	4,320	300,387	510,511	Mar 10 04:18 PM
Longsworth Todd Christopher	General Counsel	Mar 06	Sale	69.53	2,499	173,765	86,753	Mar 10 04:15 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Mar 06	Sale	69.53	3,123	217,155	140,386	Mar 10 04:13 PM
Ambrogi Michael J.	Chief Operating Officer	Mar 06	Sale	69.53	2,274	158,120	220,867	Mar 10 04:22 PM
Shah Pritesh	Chief Commercial Officer	Mar 06	Sale	66.76	6,151	410,622	86,438	Mar 10 04:20 PM
Shah Pritesh	Chief Commercial Officer	Mar 02	Sale	72.97	1,485	108,360	67,721	Mar 05 04:47 PM
Longsworth Todd Christopher	General Counsel	Feb 28	Sale	72.22	2,643	190,864	70,032	Mar 02 05:11 PM
DOYLE WILLIAM F	Executive Chairman	Feb 28	Sale	72.22	3,893	281,133	514,831	Mar 02 05:13 PM
Ambrogi Michael J.	Chief Operating Officer	Feb 28	Sale	72.22	2,673	193,031	208,726	Mar 02 05:17 PM
Shah Pritesh	Chief Commercial Officer	Feb 28	Sale	72.22	1,601	115,616	69,206	Mar 02 05:22 PM
Shah Pritesh	Chief Commercial Officer	Feb 27	Option Exercise	79.45	3,086	245,183	70,807	Mar 02 05:22 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Feb 27	Option Exercise	0.00	7,716	0	119,484	Mar 02 05:18 PM
Ambrogi Michael J.	Chief Operating Officer	Feb 27	Option Exercise	79.45	6,173	490,445	211,399	Mar 02 05:17 PM
Danziger Asaf	Chief Executive Officer	Feb 27	Option Exercise	79.45	9,259	735,628	197,348	Mar 02 05:15 PM
DOYLE WILLIAM F	Executive Chairman	Feb 27	Option Exercise	79.45	9,259	735,628	518,724	Mar 02 05:13 PM
Longsworth Todd Christopher	General Counsel	Feb 27	Option Exercise	79.45	5,556	441,424	72,675	Mar 02 05:11 PM
Shah Pritesh	Chief Commercial Officer	Feb 26	Sale	79.39	7,932	629,725	67,721	Feb 28 04:41 PM
Ambrogi Michael J.	Chief Operating Officer	Feb 25	Sale	81.16	11,647	945,224	205,226	Feb 26 05:10 PM
Longsworth Todd Christopher	General Counsel	Feb 25	Sale	81.16	8,482	688,365	67,119	Feb 26 05:14 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Feb 25	Sale	81.16	18,908	1,534,498	111,768	Feb 26 05:17 PM
Shah Pritesh	Chief Commercial Officer	Feb 25	Sale	81.16	5,067	411,217	75,653	Feb 28 04:41 PM
Danziger Asaf	Chief Executive Officer	Feb 24	Option Exercise	88.26	53,333	4,707,171	188,089	Feb 26 05:19 PM
Shah Pritesh	Chief Commercial Officer	Feb 24	Option Exercise	88.26	12,999	1,147,292	80,720	Feb 26 05:18 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Feb 24	Option Exercise	88.26	43,333	3,824,571	130,676	Feb 26 05:17 PM
Longsworth Todd Christopher	General Counsel	Feb 24	Option Exercise	88.26	21,666	1,912,241	75,601	Feb 26 05:14 PM
Ambrogi Michael J.	Chief Operating Officer	Feb 24	Option Exercise	88.26	31,199	2,753,624	216,873	Feb 26 05:10 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Jan 22	Option Exercise	7.03	2,915	20,492	88,858	Jan 24 07:11 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Jan 22	Sale	98.14	2,915	286,084	87,343	Jan 24 07:11 PM
DOYLE WILLIAM F	Executive Chairman	Jan 17	Sale	95.00	133,777	12,708,815	509,465	Jan 22 04:19 PM
PHILLIPS CHARLES G III	Director	Dec 02	Sale	88.11	6,145	541,448	3,359	Dec 04 04:23 PM
LEUNG GABRIEL	Director	Nov 25	Option Exercise	7.03	20,000	140,600	89,504	Nov 26 04:23 PM
Danziger Asaf	Chief Executive Officer	Nov 25	Option Exercise	22.00	103,000	2,266,000	237,601	Nov 26 04:28 PM
LEUNG GABRIEL	Director	Nov 25	Sale	95.00	20,000	1,900,000	69,504	Nov 26 04:23 PM
Danziger Asaf	Chief Executive Officer	Nov 25	Sale	95.00	103,000	9,785,000	134,601	Nov 26 04:28 PM
DOYLE WILLIAM F	Executive Chairman	Nov 25	Sale	96.04	16,223	1,558,057	643,242	Nov 26 04:29 PM
LEUNG GABRIEL	Director	Nov 20	Option Exercise	7.03	20,000	140,600	89,504	Nov 22 04:27 PM
DOYLE WILLIAM F	Executive Chairman	Nov 20	Sale	90.36	150,000	13,553,723	659,465	Nov 22 04:22 PM
LEUNG GABRIEL	Director	Nov 20	Sale	90.00	20,000	1,800,000	69,504	Nov 22 04:27 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Nov 18	Option Exercise	3.44	5,832	20,062	93,011	Nov 19 04:22 PM
LEUNG GABRIEL	Director	Nov 18	Option Exercise	7.03	10,000	70,300	79,504	Nov 19 04:24 PM
LEUNG GABRIEL	Director	Nov 18	Sale	85.00	10,000	850,000	69,504	Nov 19 04:24 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Nov 18	Sale	85.99	5,832	501,470	87,179	Nov 19 04:22 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Nov 15	Option Exercise	3.44	20,000	68,800	107,179	Nov 19 04:22 PM
LEUNG GABRIEL	Director	Nov 15	Option Exercise	5.33	10,000	53,273	74,761	Nov 19 04:24 PM
LEUNG GABRIEL	Director	Nov 15	Sale	83.24	10,000	832,354	69,504	Nov 19 04:24 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Nov 15	Sale	83.25	20,000	1,665,093	87,179	Nov 19 04:22 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Nov 14	Option Exercise	3.75	27,576	103,503	107,179	Nov 15 04:25 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Nov 14	Sale	81.87	27,576	2,257,689	87,179	Nov 15 04:25 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Nov 13	Option Exercise	4.34	40,000	173,500	107,179	Nov 15 04:25 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Nov 13	Sale	80.87	40,000	3,234,617	87,179	Nov 15 04:25 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Nov 12	Option Exercise	4.34	40,000	173,500	107,179	Nov 13 04:30 PM
DOYLE WILLIAM F	Executive Chairman	Nov 12	Sale	81.68	13,218	1,079,616	809,465	Nov 13 04:31 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Nov 12	Sale	80.17	40,000	3,206,810	87,179	Nov 13 04:30 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Nov 11	Option Exercise	4.23	8,600	36,405	91,979	Nov 13 04:30 PM
LEUNG GABRIEL	Director	Nov 11	Option Exercise	3.44	5,000	17,200	74,504	Nov 13 04:33 PM
LEUNG GABRIEL	Director	Nov 11	Sale	79.57	5,000	397,850	69,504	Nov 13 04:33 PM
DOYLE WILLIAM F	Executive Chairman	Nov 11	Sale	80.11	29,782	2,385,776	822,683	Nov 13 04:31 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Nov 11	Sale	80.13	8,600	689,115	87,179	Nov 13 04:30 PM
Ambrogi Michael J.	Chief Operating Officer	Nov 04	Option Exercise	20.69	80,819	1,672,467	222,631	Nov 06 04:27 PM
Ambrogi Michael J.	Chief Operating Officer	Nov 04	Sale	79.00	80,819	6,384,701	185,674	Nov 06 04:27 PM
Shah Pritesh	Chief Commercial Officer	Oct 24	Option Exercise	7.48	4,580	34,258	67,721	Oct 28 04:28 PM
LEUNG GABRIEL	Director	Oct 10	Option Exercise	3.44	5,000	17,200	74,504	Oct 15 04:12 PM
LEUNG GABRIEL	Director	Oct 10	Sale	72.28	5,000	361,400	69,504	Oct 15 04:12 PM
GROENHUYSEN WILHELMUS CM	CFO	Sep 24	Option Exercise	4.32	7,992	34,532	91,210	Sep 26 07:52 PM
GROENHUYSEN WILHELMUS CM	CFO	Sep 24	Sale	80.63	7,992	644,398	87,179	Sep 26 07:52 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Sep 16	Option Exercise	3.44	25,000	86,000	112,179	Sep 17 04:37 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Sep 16	Sale	78.93	25,000	1,973,334	87,179	Sep 17 04:37 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Sep 13	Option Exercise	3.44	25,000	86,000	112,179	Sep 17 04:37 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Sep 13	Sale	79.82	25,000	1,995,548	87,179	Sep 17 04:37 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Sep 12	Option Exercise	3.44	25,000	86,000	112,179	Sep 13 04:16 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Sep 12	Sale	79.57	25,000	1,989,278	87,179	Sep 13 04:16 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Sep 11	Option Exercise	3.44	25,000	86,000	112,179	Sep 13 04:16 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Sep 11	Sale	77.98	25,000	1,949,564	87,179	Sep 13 04:16 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Sep 10	Option Exercise	3.44	25,000	86,000	112,179	Sep 11 04:11 PM
LEUNG GABRIEL	Director	Sep 10	Option Exercise	3.44	5,000	17,200	74,504	Sep 12 04:04 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Sep 10	Sale	75.55	25,000	1,888,635	87,179	Sep 11 04:11 PM
LEUNG GABRIEL	Director	Sep 10	Sale	76.63	5,000	383,150	69,504	Sep 12 04:04 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Sep 09	Option Exercise	3.44	25,000	86,000	112,179	Sep 11 04:11 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience